All 42 planned patients in Xvivo Perfusion’s American clinical trial using STEEN Solution™ have received transplants. In the…
Read moreUS study has full number of patients and good clinical results presented for patients outside the USA
Read moreIn June all the patients were included in the clinical study with STEEN SolutionÔ according to plan. Interim results confirms previous single center experience, that initially rejected lungs evaluated with Ex Vivo Lung Perfusion (EVLP) perform similarly to standard criteria lungs after transplantation and that the use of EVLP to screen the marginal donor pool is safe. The patients will be followed up for one year after transplantation.
Read moreXVIVO Perfusion AB's share warrant program 2013/2015 is fully subscribed. A total of 195,000 warrants with the right…
Read moreInvitation to attend XVIVO Perfusion’s conference call regarding presentation of the interim report for the period January – June, 2013.
Read more
